#-supreme-cta-banner-58-387{margin-bottom:0px}#-supreme-faq-section-4-221{oxy-supreme-faq-section-faq-2-question:Consequat molestie iaculis morbi pharetra vel?;oxy-supreme-faq-section-faq-2-answer:Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes,nascetur ridiculus mus. Donec quam felis.}#-supreme-featured-news-section-53-387{oxy-supreme-featured-news-section-button-1-text:See All News & Events;oxy-supreme-featured-news-section-button-1-url:/;oxy-supreme-featured-news-section-featured-image:/wp-content/uploads/2025/10/FeaturedImage.jpg;oxy-supreme-featured-news-section-featured-tag:Case Study;oxy-supreme-featured-news-section-featured-title:How Chimerix achieved X result with Scitaris;oxy-supreme-featured-news-section-featured-url:/;oxy-supreme-featured-news-section-card-1-image:/wp-content/uploads/2025/10/Image_Card_Small.jpg;oxy-supreme-featured-news-section-card-1-tag:News Press Release;oxy-supreme-featured-news-section-card-1-title:Simultaneous target indication screening:A game of 3D chess;oxy-supreme-featured-news-section-card-1-url:/;oxy-supreme-featured-news-section-card-2-image:/wp-content/uploads/2025/10/FeaturedImage3.jpg;oxy-supreme-featured-news-section-card-2-tag:News Press Release;oxy-supreme-featured-news-section-card-2-title:Asset search and evaluation confidence in a post-truth world:How...;oxy-supreme-featured-news-section-card-2-url:/}#-supreme-who-we-are-65-402{oxy-supreme-who-we-are-enable-bg-color:true;oxy-supreme-who-we-are-enable-stats-border:true}